Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

This study has been completed.
Sponsor:
Information provided by:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT00236171
First received: October 4, 2005
Last updated: June 7, 2010
Last verified: June 2010
  Purpose

The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test


Condition Intervention
Psoriasis Vulgaris
Drug: Protopic, Advantan
Procedure: Blood and Urine Test
Procedure: coherence tomography

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

Resource links provided by NLM:


Further study details as provided by Technische Universität Dresden:

Primary Outcome Measures:
  • sum score of psoriasis plaque tests on day 11

Secondary Outcome Measures:
  • 20-MHz-ultrasound and OCT on day 11

Enrollment: 14
Study Start Date: September 2004
Study Completion Date: June 2010
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Detailed Description:

daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients older than 18 Years
  • Negative urine pregnancy test
  • Written informed consent
  • Good compliance

Exclusion Criteria:

  • Patients less than 18 years
  • Pregnant patients
  • Patients with renal insufficiency, liver diseases
  • Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study
  • Patients who used topical antipsoriatics within two weeks prior to study
  • Immunosuppressed Patients
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00236171

Locations
Germany
Technische Universität Dresden
Dresden, Sachsen, Germany, 0351
Sponsors and Collaborators
Technische Universität Dresden
Investigators
Principal Investigator: Gottfried Wozel, Professor Technische Universität Dresden
  More Information

No publications provided

Responsible Party: Gottfried Wozel, MD, Technical University Dresden
ClinicalTrials.gov Identifier: NCT00236171     History of Changes
Other Study ID Numbers: ETAPSO
Study First Received: October 4, 2005
Last Updated: June 7, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Technische Universität Dresden:
topical therapy
Psoriasis Plaque Test

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Methylprednisolone aceponate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014